OneSource Specialty Pharma has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration for its Sterile Product Division (SPD) facility in Bengaluru, with the site classified as ‘Voluntary Action Indicated’ (VAI). The report formally closes the agency’s inspection of the plant, which took place from 22 to 30 June 2026. The Bengaluru-based contract development and manufacturing organisation (CDMO) disclosed the outcome to the stock exchanges on 30 October 2026.
What the USFDA VAI classification means
The USFDA gives every inspected site one of three final classifications. According to the agency’s inspection classification guidance, a VAI outcome means investigators found objectionable conditions or practices, but the agency has decided the facility can correct them voluntarily and will not recommend regulatory action. It sits between ‘No Action Indicated’ (NAI), the cleanest result, and ‘Official Action Indicated’ (OAI), which signals an unacceptable state of compliance and can lead to warning letters or import restrictions. The FDA usually sends its final classification within 45 to 90 days of an inspection closing.
- Company: OneSource Specialty Pharma Ltd (BSE: 544292, NSE: ONESOURCE)
- Site: Sterile Product Division, Bengaluru
- Inspection dates: 22 to 30 June 2026
- Outcome: EIR issued with VAI classification, closing the inspection
- Disclosed: 30 October 2026, in a press release filed with BSE and NSE
Why the sterile unit matters for OneSource
“We are pleased to receive the EIR with VAI classification from the USFDA for our SPD facility,” said Neeraj Sharma, Managing Director and CEO, OneSource Specialty Pharma. “This inspection outcome reflects our continued commitment to maintaining high standards of quality, regulatory compliance and operational excellence across our operations. Our SPD facility plays an integral role in our sterile manufacturing capabilities, enabling us to support the evolving needs of our global partners.”
OneSource describes itself as a pure-play specialty pharmaceutical CDMO working across four modalities: drug-device combinations, biologics, sterile injectables and soft gelatin capsules. It runs five manufacturing facilities approved by global regulators and employs more than 1,600 people. For a CDMO, a clean regulatory record at a sterile site is a commercial asset as much as a compliance one, because global innovator and generic companies weigh inspection history heavily when choosing manufacturing partners for injectables and combination products.
A test that Indian plants do not always pass
The result comes at a time when USFDA scrutiny of Indian manufacturing remains intense. India Ratings and Research recently noted that 17% of USFDA inspections at Indian drug plants ended in OAI, the most serious category. Other recent outcomes have been mixed: Dr. Reddy’s Srikakulam unit also secured a VAI tag, while Granules India’s Gagillapur finished-dosage plant received a Form 483 with 11 observations after an October inspection.
Sterile injectables and pre-filled formats are also one of the fastest-growing areas of Indian pharma investment, with companies such as SCHOTT Pharma India expanding prefillable syringe and cartridge capacity for biologics. Alongside a strong quarter for CDMO revenues at peers such as Piramal Pharma, the OneSource result adds to the case that India can compete for complex, high-value outsourced manufacturing rather than only oral generics.
Key takeaways
- OneSource Specialty Pharma’s Bengaluru Sterile Product Division received a USFDA EIR with VAI classification.
- The report closes the USFDA inspection held at the site from 22 to 30 June 2026.
- The outcome strengthens OneSource’s regulatory track record as it builds a global CDMO business in biologics, sterile injectables, drug-device combinations and soft gelatin capsules.
FAQ
What did the USFDA decide on OneSource’s Bengaluru sterile facility?
The USFDA issued an Establishment Inspection Report classifying the Sterile Product Division as Voluntary Action Indicated, which closes the June 2026 inspection without recommending regulatory action.
Is a VAI classification good news for a drug plant?
Yes. VAI means any issues observed can be fixed voluntarily and the site remains in an acceptable compliance position for supplying the US market. Only NAI is a cleaner outcome.
What does OneSource Specialty Pharma make?
OneSource is a specialty pharmaceutical CDMO that develops and manufactures biologics, drug-device combinations, sterile injectables and soft gelatin capsules for global pharma companies.
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!
